Drug Profile


Alternative Names: WAY SEB 324; WY 50324

Latest Information Update: 10 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Fabre-Kramer Pharmaceuticals; Wyeth
  • Class Antidepressants; Anxiolytics; Piperazines; Pyrimidines
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 21 Mar 2002 Phase-II clinical trials in Anxiety disorders in European Union (PO)
  • 21 Mar 2002 Phase-II clinical trials in Anxiety disorders in USA (PO)
  • 21 Mar 2002 Phase-II clinical trials in Depression in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top